Suppose we name this panel as SmartThyroid®

In creating a stool DNA-based test, we sought to incorporate the most discriminating and informative biomarkers to ensure the highest possible sensitivity in detecting thyroid cancer. That is why the test includes a protein biomarker (**calcitonin**), 8 distinct DNA point mutation biomarkers (BRAF, N-RAS, H-RAS, MACF1, HMCN1, DNM1P47, BDP1, KMT2A gene), and 5 different DNA methylation biomarkers (SHOX2, SEPT9, ZNF132, APC, TP53) and 1 additional negative control. In the patent, we confirms that the appropriate amount of blood DNA is analyzed in each individual sample. This multi-marker approach is a distinguishing feature of our scientific platform.

* Above markers will be discussed again to make sure they are the best biomarkers.